F3Logic LLC lifted its holdings in shares of Medtronic PLC (NYSE:MDT) by 374.1% during the 1st quarter, Holdings Channel reports. The firm owned 19,975 shares of the medical technology company’s stock after acquiring an additional 15,762 shares during the period. F3Logic LLC’s holdings in Medtronic were worth $1,823,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the company. Trillium Asset Management LLC boosted its holdings in Medtronic by 1.1% in the first quarter. Trillium Asset Management LLC now owns 230,869 shares of the medical technology company’s stock valued at $21,027,000 after acquiring an additional 2,421 shares during the last quarter. SVA Plumb Wealth Management LLC boosted its holdings in Medtronic by 3.9% in the first quarter. SVA Plumb Wealth Management LLC now owns 75,623 shares of the medical technology company’s stock valued at $6,888,000 after acquiring an additional 2,864 shares during the last quarter. Everence Capital Management Inc. boosted its holdings in Medtronic by 30.5% in the first quarter. Everence Capital Management Inc. now owns 37,626 shares of the medical technology company’s stock valued at $3,427,000 after acquiring an additional 8,785 shares during the last quarter. Moors & Cabot Inc. boosted its holdings in Medtronic by 27.9% in the first quarter. Moors & Cabot Inc. now owns 39,126 shares of the medical technology company’s stock valued at $3,567,000 after acquiring an additional 8,527 shares during the last quarter. Finally, CIBC Asset Management Inc boosted its holdings in Medtronic by 32.0% in the first quarter. CIBC Asset Management Inc now owns 179,606 shares of the medical technology company’s stock valued at $16,358,000 after acquiring an additional 43,548 shares during the last quarter. Institutional investors and hedge funds own 81.23% of the company’s stock.

NYSE:MDT opened at $90.81 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.92 and a current ratio of 2.36. Medtronic PLC has a 12 month low of $81.66 and a 12 month high of $100.15. The stock has a market capitalization of $117.71 billion, a price-to-earnings ratio of 19.04, a P/E/G ratio of 2.18 and a beta of 0.78.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Thursday, May 23rd. The medical technology company reported $1.54 EPS for the quarter, beating the consensus estimate of $1.47 by $0.07. Medtronic had a return on equity of 13.85% and a net margin of 16.10%. The company had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.12 billion. During the same period last year, the company posted $1.42 earnings per share. The firm’s revenue was up .0% compared to the same quarter last year. Equities research analysts anticipate that Medtronic PLC will post 5.15 EPS for the current fiscal year.

A number of research analysts recently weighed in on the company. Zacks Investment Research upgraded Medtronic from a “sell” rating to a “hold” rating in a report on Monday. Wells Fargo & Co reduced their target price on Medtronic from $101.00 to $100.00 and set a “market perform” rating on the stock in a report on Thursday, April 4th. Northland Securities reiterated a “hold” rating and issued a $84.00 target price on shares of Medtronic in a report on Monday, March 18th. Citigroup lifted their target price on Medtronic from $95.00 to $101.00 and gave the company a “neutral” rating in a report on Monday, February 25th. Finally, Barclays reiterated a “buy” rating and issued a $104.00 target price on shares of Medtronic in a report on Wednesday, February 20th. Ten analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $103.39.

TRADEMARK VIOLATION NOTICE: This report was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://theolympiareport.com/2019/05/24/f3logic-llc-has-1-82-million-stake-in-medtronic-plc-mdt.html.

Medtronic Company Profile

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.

See Also: Bollinger Bands

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.